Triggers

Jump to

Ideas For Profit | Gland Pharma trades at a discount to Syngene & Divi’s; Enough triggers to invest?

With the rising prevalence of chronic diseases and growth of biologics, MC Pro recommends holding Gland Pharma. Post the recent correction and downward adjustments in estimates, Gland Pharma is trading at 17x EV/EBITDA for FY24e. Here’s why it makes for a good investment bet.
October will set near-term tone for mkt: Axis Capital

Nandan Chakraborty of Axis Capital believes that October will set the near-term tone for the market. The couple of triggers which he is looking out for is the spending in the festive season and some bold reforms likely especially in the oil and gas space after the Maharashtra and Haryana elections. That can actually set the tone in the near-term.
Market hoping for sustained earnings momentum: Motilal AMC

In an interview with CNBC-TV18, Nitin Rakesh, CEO, Motilal Oswal AMC gave his readings and outlook for the market.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Triggers

Ideas For Profit | Gland Pharma trades at a discount to Syngene & Divi’s; Enough triggers to invest?

October will set near-term tone for mkt: Axis Capital

Market hoping for sustained earnings momentum: Motilal AMC